Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

Bendamustine in Refractory / Relapsed Non Hodgkin Lymphoma

Liposomal Doxorubicin based Chemotherapy in the treatment of Relapsed Diffuse Large B-cell Lymphoma

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)

Long Term Outcomes of Relapsed/Refractory Non-Hodgkin Lymphoma:
A Single Center Experience

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

Early Complete Response after Chemotherapy as A Prognostic Indicator for Final Outcome in High Grade Non-Hodgkin’s Lymphoma Patients

Relapse in Patients with Non-Hodgkin’s Lymphpma

Treatment Outcome and Prognostic Factors in Children and Adolescents with Relapsed and Refractory Classic Hodgkin Lymphoma...

Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience